Allergy Therapeutics, a biotechnology company specialising in the treatment and diagnosis of allergic disorders, has announced the first application of VLP Peanut in peanut allergic patients has commenced.
The Phase 1 PROTECT trial is the first-in-human study evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy.
The full release can be found here.
Enter your details below and we’ll email you our printable guide featuring the symptoms to look out for and what to do in an emergency.
You’ll also receive our monthly Allergy Outlook email with our latest news, updates and resources straight to your inbox.